Tamura et al. designed an oncolytic transgene HSV encoding a secreting TRAIL (G47Δ-TRAIL) that exhibited cytotoxicity against resistant GBM cells (TRAIL or HSV) in comparison with control oncolytic HSV lacking the TRAIL gene. This evidence concerns the gene TNFSF10 and glioblastoma.